

18 March 2022

**Diaceutics PLC**

("Diaceutics" or "the Company")

**Confirmation of Directorate Change**

Further to the Company's announcement on 11 January 2022, Diaceutics confirms the appointment of Nick Roberts to the Board as Chief Financial Officer effective today, 18 March 2022.

Accordingly, the Company announces that Philip White has stepped down from the Board and as Chief Financial Officer.

The Company confirms that there are no additional disclosures required under the AIM Rules in relation to the appointment of Nick Roberts, further to the announcement dated 11 January 2022.

**Enquiries:**

**Diaceutics PLC**

Peter Keeling, Chief Executive Officer

Via Alma PR

Nick Roberts, Chief Financial Officer

**Stifel Nicolaus Europe Limited (Nomad & Broker)**

Tel: +44 (0)20 7710 7600

Ben Maddison, Stewart Wallace, Nick Adams

**Alma PR**

Tel: +44(0)20 3405 0205

Caroline Forde, Kieran Breheny, Matthew Young

diaceutics@almapr.co.uk

**About Diaceutics**

At Diaceutics we believe that every patient should have access to the right treatment at the right time. We provide the world's leading pharmaceutical companies with an end-to-end solution for the launch of precision medicine diagnostics enabled by DXRX - The Diagnostic Network®.

DXRX is the world's first diagnostic commercialisation platform for precision medicine, integrating multiple pipelines of real-world diagnostic testing data from a global network of laboratories.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [rns@lseg.com](mailto:rns@lseg.com) or visit [www.rns.com](http://www.rns.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

BOAGPUMUWUPPGCR